Analysisa | Sample size per group | ΔC (95% CI) | ΔE (95% CI) | Distribution in cost-effectiveness plane (%) | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Control | Intervention | Euros | ICER | NEb | SEc | SWd | NWe | |||
T2DM risk f | Base case | 300 | 305 | −866 (-2372;370) | 0.6 (-0.1;1.3) | -1416 | 0.6 | 4.1 | 85.9 | 9.4 |
Complete cases | 117 | 105 | −30 (-2171;1446) | 0.7 (-0.4;1.7) | -44 | 5.1 | 4.4 | 45.0 | 45.5 | |
Health care perspective | 300 | 305 | −5 (-316;272) | 0.6 (-0.1;1.3) | −8 | 2.2 | 2.4 | 47.5 | 47.9 | |
CVD risk g | Base case | 300 | 305 | −866 (-2372;370) | −0.1 (-0.4;0.2) | 6405 | 8.0 | 74.3 | 15.4 | 2.3 |
Complete cases | 116 | 104 | −19 (-2253;1410) | −0.03 (-0.34;0.29) | 642 | 29.5 | 27.8 | 21.3 | 21.5 | |
Health care perspective | 300 | 305 | −5 (-316;272) | −0.1 (-0.4;0.2) | 38 | 40.1 | 42.4 | 8.0 | 9.5 | |
QALY | Base case | 300 | 305 | −866 (-2372;370) | 0.02 (-0.02;0.05) | -50,273 | 8.2 | 76.8 | 12.9 | 2.1 |
Complete cases | 114 | 98 | 110 (-2004;1611) | 0.02 (-0.02;0.06) | 4770 | 46.4 | 40.6 | 4.2 | 8.7 | |
Health care perspective | 300 | 305 | −5 (-316;272) | 0.02 (-0.02;0.05) | −298 | 40.7 | 44.7 | 5.0 | 9.6 |